A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686)
An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Who can join: Review the eligibility criteria below.
Location: City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Yale University Cancer Center — New Haven, Connecticut
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Washington University School of Medicine (Siteman Cancer Center) — St Louis, Missouri
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Sarah Cannon Research Institute University of Oklahoma — Oklahoma City, Oklahoma
- Providence Portland Medical Center — Portland, Oregon
- Mays Cancer Center / University of Texas, San Antonio — San Antonio, Texas
- NEXT Virginia — Fairfax, Virginia
- Fred Hutch Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 766-0852
Email: clinical-trials@phanestx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer (SCLC)
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Mobile, Alabama
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Los Angeles, California
- Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Fayetteville, Arkansas
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer — Chicago, Illinois
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy — Mobile, Alabama
Explore by condition: All Small Cell Lung Cancer (SCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.